Cephalon, Inc. v. Travelers Companies, Inc.

935 F. Supp. 2d 609, 2013 WL 1294679, 2013 U.S. Dist. LEXIS 46849
CourtDistrict Court, S.D. New York
DecidedMarch 15, 2013
DocketNo. 12 Civ. 5395 (RJS)
StatusPublished
Cited by7 cases

This text of 935 F. Supp. 2d 609 (Cephalon, Inc. v. Travelers Companies, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cephalon, Inc. v. Travelers Companies, Inc., 935 F. Supp. 2d 609, 2013 WL 1294679, 2013 U.S. Dist. LEXIS 46849 (S.D.N.Y. 2013).

Opinion

MEMORANDUM AND ORDER

RICHARD J. SULLIVAN, District Judge:

Plaintiff Cephalon, Inc. (“Cephalon”) brings this action against The Travelers Companies; Inc. (“Travelers, Inc.”) and four of its subsidiaries, Travelers Indemnity Company, Travelers Casualty and Surety Company, St. Paul Fire and Marine Insurance Company, and The Standard First Insurance Company (collectively, “Travelers”), seeking a declaratory judgment that Cephalon’s off-label promotion of the pain-management drug Actiq did not violate the Food, Drug and Cosmetics Act (the “FDCA”) and that such promotion did not cause injury to Travelers. Before the Court is Travelers’ motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6) or to transfer the case pursuant to 28 U.S.C. § 1404(a). For the reasons that follow, the Court grants Travelers’ motion to dismiss.

I. Background 1

On May 23, 2012, Travelers, Inc., an insurance company incorporated in Minnesota with its principal place of business in New York, sent pre-suit settlement correspondence to Cephalon, a pharmaceutical manufacturer incorporated in Delaware with its principal place of business in Pennsylvania, accusing Cephalon of improperly promoting off-label use of its pain-management drug Actiq.2 (Am. Compl. ¶¶ 2-3, 13, 17-19.) Specifically, the letter, sent by in-house counsel, alleged that, though the FDA had approved Actiq solely for use as a pain-management drug in late-stage cancer patients, Cephalon had improperly promoted the drug as a general-use pain medication, harming Travelers, Inc., which, as a workers’ compensation insurance carrier, had paid out numerous claims for off-label use of the drug. (See Reardon Decl. Ex. 3.) Accordingly, Travelers, Inc. demanded $17.5 million in compensation for the prescription reimbursements it had issued as a result of Cephalon’s off-label promotions. (Id.) The letter warned that damages continued to accumulate at approximately $20,000 per week and requested that Cephalon “contact [Travelers, Inc.] by no later than June 15, 2012, so that [the parties could] discuss this matter further.” (Id.)

[612]*612On June 7, 2012, Cephalon responded briefly, stating that the letter “contain[ed] numerous factual and legal mistakes” and that “a detailed response to them would not be productive.” (Id. Ex. 2.) Cephalon concluded that the “claims ha[d] no merit” and “accordingly, ... decline[d the] offer.” (Id.)

On June 29, 2012, Travelers, Inc. replied with a letter from retained counsel. (Id. Ex. 3.) In the letter, Travelers, Inc.’s attorneys (1) advised that they had been retained “in connection with pursuing possible litigation”; (2) questioned the dismissive tone of Cephalon’s response given ongoing Actiq litigation “including, but not limited to, the [action] pending in the Eastern District of Pennsylvania”; and (3) asked that Cephalon reply to the letter “no later than July 13, 2012 so that [the parties] may further discuss this matter. Should [Cephalon] fail to do so, Travelers[, Inc. would] have no alternative but to commence suit in an appropriate court of law.” (Id.)

Cephalon did not respond. Instead, on July 12, 2012, it filed this declaratory action, claiming that (1) there is no private right of action under the FDCA; (2) it had not caused injury to Travelers, Inc.; and (3) Travelers, Inc. had suffered no injury. (See Compl., dated July 12, 2012, Doc. No. 1 (“Compl.”), at 5.) In its Complaint, Cephalon quoted the pre-suit correspondence, grounding its claim in the fact that “Travelers[, Inc.] has also threatened Cephalon that ‘it has every intention of pursuing its claims to recover the losses it sustained,’ and that if it does not hear from Cephalon by July 13, 2012, it ‘will have no alternative but to commence suit in an appropriate court of law.’ ” (Reardon Decl. Ex. 3; see Compl. Ex. A.)

Two weeks later, on July 24, 2012, Travelers, Inc.’s four subsidiaries — though not Travelers, Inc. itself — filed suit against Cephalon in the Eastern District of Pennsylvania asserting multiple state claims arising from the same course of conduct at issue in this action. (See Reardon Decl. Ex. 1.) The subsidiaries also named Cephalon’s parent companies, Teva, Inc. and Teva USA, as defendants. (Id.) Teva, Inc. is an Israeli corporation with its principal place of business in Israel, while Teva USA is a Delaware corporation with it principal place of business in Pennsylvania. (Id.) Each of the Travelers, Inc. subsidiaries are Connecticut corporations with their principal places of business in Connecticut. (Id.) The Eastern District of Pennsylvania was the site of a number of civil suits against Cephalon related to Actiq, including at least one pending action that is proceeding toward class certification and trial. See In re Actiq Sales & Mktg. Practices Litig., No. 07 Civ. 4492(PBT), 2012 WL 2135560 (E.D.Pa. June 13, 2012).

Thereafter, on September 20, 2012, Cephalon amended its Complaint to include the four Travelers, Inc. subsidiaries as defendants. (Doc. No. 20.) Cephalon also added factual content to its Complaint and removed the quote from Travelers, Inc.’s June 29, 2012 pre-suit letter. (See Rear-don Decl. Ex. 5 (comparing Initial and Amended Complaints).)

Travelers filed the instant motion on November 15, 2012. (Doc. No. 34.) Cephalon responded on December 17, 2012, and Travelers replied on December 28, 2012. (Doc. Nos.37, 41.) The Court heard argument on January 25, 2013.3

[613]*613II. Discussion

In its motion to dismiss, Travelers argues that the Court should decline to exercise jurisdiction over Cephalon’s action because (1) the action is improperly anticipatory, (2) it is motivated by forum shopping alone, (3) the balance of conveniences weighs in favor of the Eastern District of Pennsylvania action, and (4) allowing the action to proceed would be contrary to public policy. Alternatively, Travelers argues that the Court should transfer the action because the transfer factors favor the Eastern District of Pennsylvania as the appropriate forum. For the following reasons, the Court grants Travelers’ motion to dismiss solely on the ground that Cephalon’s declaratory action was improperly anticipatory.

The first-filed rule dictates that “[w]here there are two competing lawsuits, the first suit should have priority” in order to avoid duplicative litigation and honor the plaintiffs choice of forum. Emp’rs Ins. of Wausau v. Fox Entm’t Grp., Inc., 522 F.3d 271, 274-75 (2d Cir.2008). While the rule requires a “general presumption” that a first-filed suit has priority, the presumption is not “applied in a rigid or mechanical way.” Dornoch Ltd. v. PBM Holdings, Inc., 666 F.Supp.2d 366, 369 (S.D.N.Y.2009) (internal quotation marks omitted). Instead, the Second Circuit has recognized limited exceptions “where ‘special circumstances’ warrant giving priority to the second suit.” Emp’rs Ins. of Wausau, 522 F.3d at 275. “Special circumstances,” while “rare,” include when a “first-filed lawsuit is an improper anticipatory declaratory judgment action.” Id. at 275-76.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
935 F. Supp. 2d 609, 2013 WL 1294679, 2013 U.S. Dist. LEXIS 46849, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cephalon-inc-v-travelers-companies-inc-nysd-2013.